| 2026-02-26 00:55:48 |
statusModule.statusVerifiedDate: 2025-12 |
statusModule.statusVerifiedDate: 2026-02 |
| 2026-02-26 00:55:48 |
statusModule.lastUpdateSubmitDate: 2025-12-16 |
statusModule.lastUpdateSubmitDate: 2026-02-23 |
| 2026-02-26 00:55:48 |
statusModule.lastUpdatePostDateStruct.date: 2025-12-17 |
statusModule.lastUpdatePostDateStruct.date: 2026-02-25 |
| 2026-02-26 00:55:48 |
contactsLocationsModule.centralContacts.[0]name: BMS Study Connect Contact Center www.BMSStudyConnect.com |
contactsLocationsModule.centralContacts.[0]name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com |
| 2026-02-26 00:55:48 |
contactsLocationsModule.locations.[3]status: COMPLETED |
contactsLocationsModule.locations.[3]status: ACTIVE_NOT_RECRUITING |
| 2026-02-26 00:55:48 |
contactsLocationsModule.locations.[7]status: COMPLETED |
contactsLocationsModule.locations.[7]status: ACTIVE_NOT_RECRUITING |
| 2026-02-26 00:55:48 |
- |
root['ipdSharingStatementModule'] (Added) |
| 2026-03-21 02:05:09 |
contactsLocationsModule.locations.[39]city: Napoli |
contactsLocationsModule.locations.[39]city: Naples |
| 2026-03-21 02:05:09 |
contactsLocationsModule.locations.[39]geoPoint.lat: 40.87618 |
contactsLocationsModule.locations.[39]geoPoint.lat: 40.85216 |
| 2026-03-21 02:05:09 |
contactsLocationsModule.locations.[39]geoPoint.lon: 14.5195 |
contactsLocationsModule.locations.[39]geoPoint.lon: 14.26811 |
| 2026-04-07 02:32:47 |
statusModule.statusVerifiedDate: 2026-02 |
statusModule.statusVerifiedDate: 2026-04 |
| 2026-04-07 02:32:47 |
statusModule.lastUpdateSubmitDate: 2026-02-23 |
statusModule.lastUpdateSubmitDate: 2026-04-03 |
| 2026-04-07 02:32:47 |
statusModule.lastUpdatePostDateStruct.date: 2026-02-25 |
statusModule.lastUpdatePostDateStruct.date: 2026-04-06 |
| 2026-04-07 02:32:47 |
contactsLocationsModule.locations.[3]facility: Local Institution - 0062 |
contactsLocationsModule.locations.[3]facility: University of Iowa |
| 2026-04-07 02:32:47 |
contactsLocationsModule.locations.[3]status: ACTIVE_NOT_RECRUITING |
contactsLocationsModule.locations.[3]status: RECRUITING |
| 2026-04-07 02:32:47 |
contactsLocationsModule.locations.[7]facility: Local Institution - 0001 |
contactsLocationsModule.locations.[7]facility: Providence Cancer Center Oncology and Hematology Care- Eastside |
| 2026-04-07 02:32:47 |
contactsLocationsModule.locations.[7]status: ACTIVE_NOT_RECRUITING |
contactsLocationsModule.locations.[7]status: RECRUITING |
| 2026-04-07 02:32:47 |
- |
root['contactsLocationsModule']['locations'][3]['contacts'] (Added) |
| 2026-04-07 02:32:47 |
- |
root['contactsLocationsModule']['locations'][7]['contacts'] (Added) |
| 2026-05-26 02:38:39 |
statusModule.lastUpdateSubmitDate: 2026-04-03 |
statusModule.lastUpdateSubmitDate: 2026-04-08 |
| 2026-05-26 02:38:39 |
statusModule.lastUpdatePostDateStruct.date: 2026-04-06 |
statusModule.lastUpdatePostDateStruct.date: 2026-04-13 |
| 2026-05-26 02:38:39 |
contactsLocationsModule.locations.[19]contacts.[0]phone: 9053170886 |
contactsLocationsModule.locations.[19]contacts.[0]phone: 905-387-9495 |
| 2026-06-05 03:53:46 |
identificationModule.briefTitle: A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors |
identificationModule.briefTitle: A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors |
| 2026-06-05 03:53:46 |
identificationModule.officialTitle: A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors |
identificationModule.officialTitle: A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors |
| 2026-06-05 03:53:46 |
statusModule.statusVerifiedDate: 2026-04 |
statusModule.statusVerifiedDate: 2026-06 |
| 2026-06-05 03:53:46 |
statusModule.primaryCompletionDateStruct.date: 2028-07-07 |
statusModule.primaryCompletionDateStruct.date: 2031-08-31 |
| 2026-06-05 03:53:46 |
statusModule.completionDateStruct.date: 2028-07-07 |
statusModule.completionDateStruct.date: 2031-08-31 |
| 2026-06-05 03:53:46 |
statusModule.lastUpdateSubmitDate: 2026-04-08 |
statusModule.lastUpdateSubmitDate: 2026-06-02 |
| 2026-06-05 03:53:46 |
statusModule.lastUpdatePostDateStruct.date: 2026-04-13 |
statusModule.lastUpdatePostDateStruct.date: 2026-06-04 |
| 2026-06-05 03:53:46 |
descriptionModule.briefSummary: The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors. |
descriptionModule.briefSummary: The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors. |
| 2026-06-05 03:53:46 |
designModule.designInfo.allocation: NON_RANDOMIZED |
designModule.designInfo.allocation: RANDOMIZED |
| 2026-06-05 03:53:46 |
designModule.enrollmentInfo.count: 949 |
designModule.enrollmentInfo.count: 1109 |
| 2026-06-05 03:53:46 |
outcomesModule.primaryOutcomes.[2]measure: Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria |
outcomesModule.primaryOutcomes.[2]measure: Number of deaths |
| 2026-06-05 03:53:46 |
- |
Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria |
| 2026-06-05 03:53:46 |
- |
* Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis. |
| 2026-06-05 03:53:46 |
- |
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable. |
| 2026-06-05 03:53:46 |
- |
* Eastern Cooperative Oncology Group Performance Status of 0 or 1. |
| 2026-06-05 03:53:46 |
- |
* Radiographically documented progressive disease on or after the most recent therapy. |
| 2026-06-05 03:53:46 |
- |
* Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated. |
| 2026-06-05 03:53:46 |
- |
* Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant. |
| 2026-06-05 03:53:46 |
- |
Exclusion Criteria |
| 2026-06-05 03:53:46 |
- |
* Women` to `Inclusion Criteria |
| 2026-06-05 03:53:46 |
- |
* Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis. |
| 2026-06-05 03:53:46 |
- |
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable. |
| 2026-06-05 03:53:46 |
- |
* Eastern Cooperative Oncology Group Performance Status of 0 or 1. |
| 2026-06-05 03:53:46 |
- |
* Radiographically documented progressive disease on or after the most recent therapy. |
| 2026-06-05 03:53:46 |
- |
* Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated. |
| 2026-06-05 03:53:46 |
- |
* Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant. |
| 2026-06-05 03:53:46 |
- |
Exclusion Criter` |
| 2026-06-05 03:53:46 |
contactsLocationsModule.locations.[24]facility: Universitaetsklinikum Ulm |
contactsLocationsModule.locations.[24]facility: Local Institution - 0044 |
| 2026-06-05 03:53:46 |
contactsLocationsModule.locations.[24]status: RECRUITING |
contactsLocationsModule.locations.[24]status: COMPLETED |
| 2026-06-05 03:53:46 |
root['contactsLocationsModule']['locations'][24]['contacts'] (Removed) |
- |
| 2026-07-28 00:26:03 |
statusModule.lastUpdateSubmitDate: 2026-06-02 |
statusModule.lastUpdateSubmitDate: 2026-06-29 |
| 2026-07-28 00:26:03 |
statusModule.lastUpdatePostDateStruct.date: 2026-06-04 |
statusModule.lastUpdatePostDateStruct.date: 2026-06-30 |
| 2026-07-28 00:26:03 |
contactsLocationsModule.locations.[18]facility: BC Cancer Vancouver |
contactsLocationsModule.locations.[18]facility: Local Institution - 0030 |
| 2026-07-28 00:26:03 |
contactsLocationsModule.locations.[18]status: RECRUITING |
contactsLocationsModule.locations.[18]status: COMPLETED |
| 2026-07-28 00:26:03 |
contactsLocationsModule.locations.[22]facility: The Ottawa Hospital Cancer Centre |
contactsLocationsModule.locations.[22]facility: Local Institution - 0016 |
| 2026-07-28 00:26:03 |
contactsLocationsModule.locations.[22]status: RECRUITING |
contactsLocationsModule.locations.[22]status: COMPLETED |
| 2026-07-28 00:26:03 |
root['contactsLocationsModule']['locations'][18]['contacts'] (Removed) |
- |
| 2026-07-28 00:26:03 |
root['contactsLocationsModule']['locations'][22]['contacts'] (Removed) |
- |